Overview

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery
Phase:
Phase 2
Details
Lead Sponsor:
Allon Therapeutics
Treatments:
Polystyrene sulfonic acid